2. Search Result
Search Result
Results for "

mastocytosis

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13936
    1-Methylimidazoleacetic acid

    1-Methylimidazole-4-acetic acid

    		 Endogenous Metabolite Others
    1-Methylimidazoleacetic acid (1-Methylimidazole-4-acetic acid) is a histamine metabolite in urine that can be used in the study of mastocytosis .
    1-Methylimidazoleacetic acid
  • HY-152839
    Elenestinib

    BLU-263

    		 c-Kit Cancer
    Elenestinib (BLU-263) is an orally active inhibitor of Tyrosine kinase with an IC50 value of 6 nM for KIT D816V. Elenestinib minimally penetrates the blood-brain barrier. Elenestinib can be used in the study of systemic mastocytosis .
    Elenestinib
  • HY-145557
    Bezuclastinib

    CGT9486; PLX 9486

    		 c-Kit Cancer
    Bezuclastinib (CGT9486) is an orally active, highly selective tyrosine kinase inhibitor with potent activity against KIT D816V. Bezuclastinib can be used for the research of nonadvanced systemic mastocytosis (NonAdvSM) .
    Bezuclastinib
  • HY-152839A
    Elenestinib phosphate

    BLU-263 phosphate

    		 c-Kit Cancer
    Elenestinib (BLU-263) phosphate is an orally active inhibitor of Tyrosine kinase with an IC50 of 0.2 nM for KIT D816V. Elenestinib phosphate minimally penetrates the blood-brain barrier. Elenestinib phosphate can be used in the study of systemic mastocytosis .
    Elenestinib phosphate
  • HY-101005
    N-Methylhistamine dihydrochloride

    Nα-Methylhistamine dihydrochloride

    		 Histamine Receptor Inflammation/Immunology
    N-Methylhistamine (Nα-Methylhistamine) dihydrochloride is a potent agonist of the histamine H3 receptor, exhibiting significant implications in the diagnosis and management of mastocytosis. N-Methylhistamine (dihydrochloride) also serves as a biomarker for assessing mast cell accumulation in clinical evaluations.
    N-Methylhistamine dihydrochloride
  • HY-107458
    AP23848

    		c-Kit Cancer
    AP23848 is an ATP-dependent kinase inhibitor that effectively and selectively targets the Kit activation loop mutation both in vitro and in vivo, showing anti-tumor activity. AP23848 can inhibit the phosphorylation of the activated Kit mutation and tumor growth in mice, making it suitable for targeting diseases with the D816V mutation, such as systemic mastocytosis (SM) and acute myeloid leukemia (AML) research .
    AP23848

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: